ASX:MDR

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

MedAdvisor Limited, together with its subsidiaries, develops and delivers software for personal medication management in Australia. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.

Share Price & News

How has MedAdvisor's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: MDR is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: MDR's weekly volatility has decreased from 15% to 7% over the past year.


Market Performance


7 Day Return

-1.4%

MDR

7.9%

AU Healthcare Services

0.1%

AU Market


1 Year Return

-33.0%

MDR

18.3%

AU Healthcare Services

-1.6%

AU Market

Return vs Industry: MDR underperformed the Australian Healthcare Services industry which returned 18.3% over the past year.

Return vs Market: MDR underperformed the Australian Market which returned -1.6% over the past year.


Shareholder returns

MDRIndustryMarket
7 Day-1.4%7.9%0.1%
30 Day-1.4%13.6%2.3%
90 Day-9.0%16.8%9.8%
1 Year-32.0%-33.0%18.9%18.3%1.7%-1.6%
3 Year2.9%1.4%137.6%127.5%25.7%10.1%
5 Year39.1%37.1%257.7%250.6%70.7%37.2%

Long-Term Price Volatility Vs. Market

How volatile is MedAdvisor's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is MedAdvisor undervalued compared to its fair value and its price relative to the market?

5.26x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MDR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate MDR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: MDR is unprofitable, so we can't compare its PE Ratio to the XX Healthcare Services industry average.

PE vs Market: MDR is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MDR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: MDR is good value based on its PB Ratio (5.3x) compared to the AU Healthcare Services industry average (5.5x).


Next Steps

Future Growth

How is MedAdvisor forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MedAdvisor has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has MedAdvisor performed over the past 5 years?

-35.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: MDR is currently unprofitable.

Growing Profit Margin: MDR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: MDR is unprofitable, and losses have increased over the past 5 years at a rate of 35.9% per year.

Accelerating Growth: Unable to compare MDR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MDR is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-8.6%).


Return on Equity

High ROE: MDR has a negative Return on Equity (-57.46%), as it is currently unprofitable.


Next Steps

Financial Health

How is MedAdvisor's financial position?


Financial Position Analysis

Short Term Liabilities: MDR's short term assets (A$14.6M) exceed its short term liabilities (A$3.0M).

Long Term Liabilities: MDR's short term assets (A$14.6M) exceed its long term liabilities (A$1.2M).


Debt to Equity History and Analysis

Debt Level: MDR is debt free.

Reducing Debt: MDR has no debt compared to 5 years ago when its debt to equity ratio was 267.5%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: MDR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: MDR has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 31.2% each year.


Next Steps

Dividend

What is MedAdvisor current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate MDR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MDR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MDR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MDR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of MDR's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.9yrs

Average management tenure


CEO

Robert Read

5.17yrs

Tenure

AU$461,073

Compensation

Mr. Robert Read, BComm(Mgt), BA(Psych), GAICD., has been the Chief Executive Officer of MedAdvisor Limited since November 12, 2015 and also serves as its Managing Director. Mr. Read served as Managing Dire...


CEO Compensation Analysis

Compensation vs Market: Robert's total compensation ($USD358.92K) is about average for companies of similar size in the Australian market ($USD295.31K).

Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Robert Read
MD, CEO & Executive Director5.17yrsAU$461.07k0.81%
A$ 1.0m
Joshua Swinnerton
Founder5.17yrsAU$282.70k4.32%
A$ 5.4m
Simon Glover
Chief Financial Officer1.5yrsAU$264.82kno data
Carlo Campiciano
Company Secretary5.08yrsAU$204.07k0.95%
A$ 1.2m
Craig Schnuriger
Interim Chief Technology Officer0.58yrno datano data
Naomi Lawrie
Company Secretary & General Counsel0.42yrno datano data
Jennifer Duraisingam
Corporate Communications Managerno datano datano data
Theo Antonopoulos
Head of Sales & Marketing5.08yrsno datano data
Ruba El-Afifi
Executive General Manager of People & Culture2.33yrsno datano data
Jamal Butt
Head of Commercialno datano datano data
Keith Kiarsis
President & CEO of the US businessno datano datano data
Steve Watt
Chief Revenue Officer1yrno datano data

1.9yrs

Average Tenure

Experienced Management: MDR's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Robert Read
MD, CEO & Executive Director5.17yrsAU$461.07k0.81%
A$ 1.0m
Joshua Swinnerton
Founder5.17yrsAU$282.70k4.32%
A$ 5.4m
Jeffrey Sherman
Non-Executive Director1.25yrsno datano data
Peter Bennetto
Non-Executive Director7.17yrsAU$75.56k0.45%
A$ 566.6k
Sandra Hook
Independent Non-Executive Director5yrsAU$280.20k0.070%
A$ 87.5k
Christopher Ridd
Non-Executive Chairman of the Board0.92yrAU$44.50k0.051%
A$ 64.5k
Arthur Charlaftis
Member of Advisory Board4.83yrsno datano data
Jim Xenos
Non-Executive Director5.17yrsAU$49.28k5.71%
A$ 7.2m
Mike Da Gama
Member of Advisory Board4.83yrsAU$25.89kno data
Nick England
Member of Advisory Board4.83yrsno datano data

4.9yrs

Average Tenure

Experienced Board: MDR's board of directors are considered experienced (4.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: MDR insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.2%.


Top Shareholders

Company Information

MedAdvisor Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: MedAdvisor Limited
  • Ticker: MDR
  • Exchange: ASX
  • Founded: 2010
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$125.817m
  • Shares outstanding: 359.48m
  • Website: https://www.medadvisor.com.au

Location

  • MedAdvisor Limited
  • 971 Burke Road
  • Level 2
  • Camberwell
  • Victoria
  • 3124
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MDRASX (Australian Securities Exchange)YesShare CapitalAUAUDDec 2015
MDRCHIA (Chi-X Australia)YesShare CapitalAUAUDDec 2015

Biography

MedAdvisor Limited, together with its subsidiaries, develops and delivers software for personal medication management in Australia. It develops and deploys the MedAdvisor, a medication and adherence platfo...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/15 07:04
End of Day Share Price2021/01/15 00:00
Earnings2020/06/30
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.